fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Dostarlimab effective in rectal cancer subset

Written by | 5 Jul 2022

PD-1 blockade with adjuvant dostarlimab in mismatch repair–deficient, locally advanced rectal cancer shows signs of high efficacy, researchers reported on June 5, 2022 in the NEJM/ New England… read more.

Researchers develop hybrid sensor that can help diagnose cancer

Written by | 3 Jul 2022

A team of researchers from HSE University, Skoltech, MPGU, and MISIS have developed a nanophotonic-microfluidic sensor whose potential applications include cancer detection, monitoring and treatment response assessment. Today,… read more.

App to help doctors help patients with leukemia

Written by | 28 Jun 2022

lymphocytic leukaemia (CLL) will develop a serious infection or need early treatment for CLL. 10 percent of these risk dying within a month. In order to help these… read more.

New approach to prostate cancer improves 5-year survival

Written by | 26 Jun 2022

A combination of hormone therapy and pelvic lymph node radiation improves survival of prostate cancer patients, researchers reported on May 26, 2022 in The Lancet. “We can now… read more.

Improved treatment emerges for mantle cell lymphoma

Written by | 25 Jun 2022

Addition of ibrutinib to standard chemotherapy for patients over 65 with previously untreated mantle cell lymphoma (MCL) has led to significantly improved progression-free survival, researchers reported on June… read more.

Sun safety for children – new research will explore the role of primary schools in preventing skin cancer

Written by | 17 Jun 2022

With skin cancer rates rising, much of it preventable, a new research project is to explore the role of primary schools in Wales and assess the effectiveness of… read more.

Immunity boosting treatment enhances CAR-T cell therapy for blood cancers

Written by | 15 Jun 2022

Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are… read more.

Study finds COVID-19 pandemic reduced breast, cervical, colorectal cancer screenings by millions

Written by | 10 Jun 2022

New findings led by researchers at the American Cancer Society (ACS) show the number of women in the United States who reported having a recent (in the past year) breast cancer… read more.

“Breakthrough” COVID infections more prevalent and more dangerous for cancer patients

Written by | 3 Jun 2022

Breakthrough COVID-19 infection is more prevalent among vaccinated cancer patients than in the general population, and the results are more dangerous, researchers reported on April 8, 2022 in… read more.

Prostate cancer linked to increased risk of venous thromboembolism

Written by | 1 Jun 2022

Researchers from Sweden have reported that, compared with men with no prostate cancer, men diagnosed with prostate cancer have a significantly higher risk of developing venous thromboembolism (VTE)… read more.

One-off treatment shown to prevent long term side effects of cancer radiotherapies

Written by | 24 May 2022

A new study has found that a simple, one-off treatment was able to prevent long term side effects of cancer radiotherapies. There are about 2 million cancer survivors… read more.

Many pathologists agree overdiagnosis of skin cancer happens, but don’t change diagnosis behavior

Written by | 10 May 2022

As the most serious type of skin cancer, a melanoma diagnosis carries emotional, financial and medical consequences. That’s why recent studies finding that there is an overdiagnosis of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.